CPMV Stock Overview
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Mosaic ImmunoEngineering, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.60 |
52 Week High | US$1.00 |
52 Week Low | US$0.30 |
Beta | -1.43 |
1 Month Change | 85.59% |
3 Month Change | 3.45% |
1 Year Change | -40.00% |
3 Year Change | -79.02% |
5 Year Change | n/a |
Change since IPO | -87.76% |
Recent News & Updates
Recent updates
Shareholder Returns
CPMV | US Biotechs | US Market | |
---|---|---|---|
7D | 91.6% | 0.5% | -0.7% |
1Y | -40.0% | 1.2% | 22.8% |
Return vs Industry: CPMV underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: CPMV underperformed the US Market which returned 22.3% over the past year.
Price Volatility
CPMV volatility | |
---|---|
CPMV Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CPMV's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CPMV's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 6 | Steven King | www.mosaicie.com |
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.
Mosaic ImmunoEngineering, Inc. Fundamentals Summary
CPMV fundamental statistics | |
---|---|
Market cap | US$4.26m |
Earnings (TTM) | -US$1.01m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs CPMV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CPMV income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$1.01m |
Earnings | -US$1.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.14 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -22.4% |
How did CPMV perform over the long term?
See historical performance and comparison